Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe9

The companies enter into a…

Novadip Biosciences Raises Additional EUR 40 Million Bringing Total Company Funding to EUR 88 Million

Funding will support development of…

Coave Therapeutics Strengthens Board of Directors

Paris, France, October 20th, 2022…

ExeVir Bio Forges Ahead with Unique Next Generation COVID-19 Therapy and Appoints Dr. Jeanne Bolger as Chair of the Board of Directors

Targeting final lead therapy selection,…

Indigo Diabetes Announces First Participant Enrolled in the SHINE Clinical Trial

BELGIUM – Ghent, September 29,…

Coave Therapeutics to Collaborate with World-Renowned Institute of Neurodegenerative Diseases of Bordeaux to Develop Gene Therapy Programs Targeting Protein Degradation in Neurodegenerative Disorders

Coave Therapeutics to Collaborate with…

Minoryx‘s Marketing Authorization Application for its lead candidate leriglitazone validated by EMA for orphan indication X-linked Adrenoleukodystrophy (X-ALD

Minoryx‘s Marketing Authorization Application for…

Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium

Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States…

Cardior Announces First Patient Dosed in Phase 2 Study Evaluating Efficacy and Safety of Non-coding RNABased Lead Candidate CDR132L in Heart Failure Patients PostMyocardial Infarction

Cardior Announces First Patient Dosed…

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén

Immunic, Inc. Strengthens Its Board…